Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • Tandem Diabetes Care Inc (NASDAQ:TNDM) has agreed to acquire AMF Medical SA, the privately held Swiss developer of the investigational Sigi Patch Pump.
  • It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology.
  • The acquisition expands Tandem's type 1 and type 2 addressable market opportunities.
  • Tandem Diabetes Care will acquire AMF Medical under the following financial terms of the agreement:
  • A previous strategic investment of CHF 8.0 million was paid in Q3 of 2022.
  • A cash payment of CHF 62.4 million is due at closing.
  • Additional contingent earnout payments of up to CHF 129.6 million, in aggregate, are payable upon achieving certain milestones.
  • The transaction is expected to close in January 2023.
  • Price Action: TNDM shares are down 3.40% at $42.16 on the last check Tuesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: M&ANewsHealth CareMoversTrading IdeasGeneralBriefs